ABSTRACT
We describe a 28-year-old Caucasian female with vigorexy, who had no previous ocular history. She presented with bilateral gradual painless reduction in vision over the past 3 weeks. She had been taking niacin supplements, averaging 500â¯mg daily, for 7 years. Fundus examination revealed bilateral CME, which was confirmed by ocular coherence tomography scan. Fundus fluorescein angiography did not reveal any fluid leakage. Niacin supplementation was discontinued, and after 2 months, the CME had completely resolved, and the best corrected visual acuities improved to 1 in both eyes.
ABSTRACT
El síndrome de Susac es una entidad rara, descrito como una tríada clínica de encefalopatía, sordera neurosensorial y trastorno visual por oclusión de ramas de arteria retiniana, aunque no siempre se presenta como tríada, se carac- teriza por evolución prolongada y no necesariamente secuencial ni correlacionada con la presentación clínica, que es variable, por lo que el diagnóstico puede ser tardío e influenciar el pronóstico. Es más frecuente en mujeres. La patogénesis se considera como una enfermedad microangiopática autoinmune a nivel cerebral, retiniana y coclear. Descripción del caso clínico: Se presenta caso de paciente masculino de 36 años, con cuadro de cefalea, cambios conductuales, déficit motor y sensitivo de hemicuerpo derecho, seguido por alteraciones visuales y disminución de per- cepción auditiva. Se realiza diagnóstico con imagen de resonancia magnética cerebral con lesiones redondeadas hiperintensas en cuerpo calloso y regiones cortico-subcorticales; audiometría con sordera neurosensorial; y angiografía con fluoresceína de retina con obstrucción de arteria retiniana, confirmando este último recur- so el diagnóstico de síndrome de Susac. Conclusiones: Esta es una enfermedad probablemente subdiagnosticada que debe ser contemplada en el diagnóstico diferencial de enfermedades vas- culares cerebrales o desmielinizantes e implica importantes com- plicaciones y secuela sobre el paciente, el diagnóstico temprano influencia el pronóstico, por lo que debe establecerse tratamiento agresivo y temprano a fin de minimizar daños...(AU)
Subject(s)
Humans , Male , Adult , Susac Syndrome/diagnosis , Hearing Loss, Sensorineural/complications , Brain Diseases , Fluorescein Angiography/methodsABSTRACT
RESUMEN Se informa el caso de una paciente con enfermedad de Gaucher (EG) tipo 3b con mutación homocigota en el gen GBA (c.1448T>C p.L483P) (L444P). Se describen los hallazgos oculares característicos de esta mutación, que incluyen condensaciones vítreas y edema macular. Hasta donde sabemos, es el primer caso informado en Colombia con estas características. Se presenta además una revisión sobre las manifestaciones oculares de esta enfermedad.
SUMMARY We report the case of a patient with Gaucher disease (GD) type 3b, with a homozygous GBA gene mutation (c.1448T > C p.L483P) (L444P). Ocular findings characteristic of this mutation are described, including vitreous condensation and macular edema. To our knowledge this is the first case reported in Colombia with these characteristics. A review of the ocular manifestations of this disease is also presented.
RESUMO Se informa o caso de uma paciente com doença de Gaucher (EG) tipo 3b com mutação homozigoto no gene GBA (c.1448T>C p.L483P) (L444P). Se descrevem as descobertas oculares características desta mutação, que incluem condensações vítreas e edema macular. Até onde sabemos, é o primeiro caso informado na Colômbia com estas características. Se apresenta ademais uma revisão sobre as manifestações oculares desta doença.
Subject(s)
Humans , Female , Adolescent , Retinal Diseases , Gaucher Disease , Eye ManifestationsABSTRACT
INTRODUCTION: Pars planitis (PP) is a form of intermediate uveitis that manifests with several posterior segment complications, including cystoid macular edema (CME) and epiretinal membrane formation (ERM). On the presence of CME the patient is usually treated with anti-inflammatory and/or immunosuppressive drugs. However the presence of CME may coexist with ERM formation, and therefore the treatment could be different. PURPOSE: To determine the association between ERM and CME in PP. MATERIALS AND METHODS: Case control series. The charts of patients diagnosed with PP were retrospectively reviewed. All patients had fluorescein angiogram (FA) and spectral domain optical coherence tomography (SD-OCT). Presence of ERM was determined by SD-OCT, while CME was determined by FA. Contingency tables were used to determine the risk of developing CME with ERM. RESULTS: 31 eyes presented ERM. 16 eyes presented CME. Relative risk to have CME and ERM was 0.971, with a P value of 0.77 (χ(2)). CONCLUSIONS: There is no association between ERM formation and the development of CME. There is no evidence to suggest a surgical approach as first line of treatment with the presence of ERM in PP.
